Construction of a bispecific single-chain antibody derivative is described that consists of two different single-chain Fv Pfu polymerase, we used the two primers 5'lightEco5 and 3'lightBgl2, flanking the light chain, and 5'heavyEco5 and 3'heavyBspEl, flanking the heavy chain. For detailed specification of primers, see below. Two independent clones of each V domain were sequenced and compared for identity.
expressed in CHO cells as a fully functional protein, while its periplasmic expression in Escherichia coli resulted in a nonfunctional protein only. The antigen-binding properties of the bispecific single-chain antibody are indistinguishable from those of the corresponding univalent single-chain Fv fragments. By redirecting human peripheral T lymphocytes against 17-lA-positive tumor cells, the bispecific antibody proved to be highly cytotoxic at nanomolar concentrations as demonstrated by 5tCr release assay on various cell lines. The described bispecific construct has a molecular mass of 60 kDa and can be easily purified by its C-terminal histidine tail on a Ni-NTA chromatography column. As bispecific antibodies have already been shown to be effective in vivo in experimental tumor systems as well as in phase-one clinical trials, the small CD3/17-lA-bispecific antibody may be more efficacious than intact antibodies against minimal residual cancer cells.
The 17-1A or EpCAM antigen, a surface glycoprotein expressed by cells of simple epithelia, has been shown to be a rewarding target for monoclonal antibody therapy against disseminated tumor cells in patients with minimal residual colorectal cancer (1) . Since treatment with intact anti-17-1A antibody decreased the 5-year mortality rate of the treated patients by only 30%, we tried to improve the efficacy of this approach by designing a bispecific antibody, which could engage cytotoxic T cells against isolated metastatic 17-lApositive tumor cells. Target cell-bound bispecific antibodies are known to trigger cytotoxic activity of T lymphocytes by crosslinking of CD3 (2, 3) , irrespective of T-cell receptor specificity, major histocompatibility complex (MHC) restriction, or MHC down regulation on tumor cells (4) . Additional activation mediated by costimulatory molecules such as CD28 and CD2 has been shown to increase target cell lysis (5, 6) . Both in vitro and in vivo results indicate that bispecific antibodies in general are more effective in tumor cell elimination than antibody-dependent cellular cytotoxicity or complement activity of monoclonal antibodies (7, 8) , the latter of which is inhibited by membrane-bound proteins such as CD59 or decay accelerating factor, controlling the cytolytic effect of complement. So far, approaches to construct bispecific antibodies like hybrid hybridomas (9, 10) , chemical linkage, renaturation from bacterial inclusion bodies (11, 12) , or the use of noncovalent coupling in diabodies (13) or Jun-Fos constructs (14) suffer from low yields, occurrence of ill-defined by-products, or laborious purification procedures. To overcome these prob-
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lems, we developed a procedure by which two single-chain Fv (sc-Fv) fragments (15, 16) Proc. Natl. Acad. Sci. USA 92 (1995) periplasmic signal sequence OmpA,and a 5'-terminal Flag epitope (Kodak) for detection. The periplasmic expression was performed in E. coli strain JM83 according to the procedure described by Pluckthun et al. (20) .
Construction of Bispecific Single-Chain Fragments and Eukaryotic Expression. Construction of the bispecific singlechain antibody was performed in three steps ( Fig. 1 ).
(i) To introduce the Gly4-Ser1 or (Gly4-Serl)3 linker sequences between the VH regions of the M79 sc-Fv fragment and the anti-CD3 sc-Fv fragment and in order to add a 3'-terminal histidine tail, we generated a PCR fragment of the anti-CD3 sc-Fv fragment DNA with the two primers 5'heavyCD31inker5 and 5'heavyCD31inkerl5 and with 3'lightCD3His (Taq polymerase) and subcloned it with the BspEI and HindIII restriction enzymes into the vector already containing the M79 sc-Fv fragment.
(ii) A synthetic DNA oligodimer (5'leaderFlag and 3'leaderFlag) coding for a eukaryotic secretory signal sequence together with the Flag epitope was subcloned into the same vector with theXba I and EcoRV enzymes. We anticipated that a protein beginning with the Flag epitope would be secreted by eukaryotic cells (21) .
(iii) Finally, the bsc-Ab fragment was subcloned into a vector for stable eukaryotic expression. This vector contained the promoter of human elongation factor la, kindly provided by S. Nagata (22) , followed by a multiple cloning site and an internal ribosomal binding site (23) , which allows bicistronic expression of the construct and dihydrofolate reductase (DHFR) used as a selection marker (P.K., unpublished data). The expression was performed in DHFR-deficient CHO cells as described by Kaufman (24) . The cells were transfected by electroporation and grown for selection in nucleoside-free a-MEM supplemented with dialyzed 10% fetal calf serum (FCS) (GIBCO) and 2 mM L-glutamine. To increase the expression rate by gene amplification, the transfectants were subsequently exposed to 20 nM methotrexate. For production of bsc-Ab cells were grown in roller bottles (Falcon).
List of Primers. The following primers were used: 5'lightEcoV, 5'-aagatatccagctgacccagtctcca-3'; 3'lightBgl2, 5 Purification with Flag Tag and Histidine Tail. For purification with the Flag Ml affinity column (Kodak) we dialyzed the periplasmic fraction of the bacterial lysates against optimal buffer (0.15 M NaCl/0.01 M sodium phosphate/1.0 mM CaCl2, pH 7.4). To the supernatant from CHO transfectants we added CaCl2 to a final concentration of 1.0 mM. For further steps, we followed the suggested protocol (Kodak). The bsc-Ab containing a histidine tail was purified by affinity chromatography on a Ni-NTA column (Quiagen). The bound bsc-Ab was eluted with a gradient of imidazole from 0 to 500 mM increasing in 100 mM steps. Elution occurred at a concentration of 200 mM imidazole as a distinct peak. The eluted proteins were dialyzed against phosphate-buffered saline (PBS) and sterile-filtrated. (Fig. 3) . No binding was detectable on cell lines X63, U937, and K562, all of which are known to express neither 17-lA nor CD3, whereas 17-lA-transfected X63 and 17-lA-positive HT29 cells also bound the bsc-Ab.
The bsc-Ab and the corresponding monovalent sc-Fv fragments expressed in E. coli are expected to have similar binding affinities. For comparison, specific mean channel fluorescence on 17-lA-positive Kato cells was plotted against molar concentrations of bsc-Ab or the 17-lA-specific sc-Fv fragment (Fig. 4A) . The results proved to be almost identical and could be confirmed by ELISA (Fig. 4B ) with immobilized recombinant soluble 17-lA (P.K., unpublished data). The CD3-binding affinity of the bsc-Ab was found to resemble that of the corresponding anti-CD3 sc-Fv fragment by plotting specific mean channel fluorescence on CD3-positive Jurkat cells against the corresponding concentration values (Fig. 4C) . The bsc-Ab and the monovalent single-chain fragments were detected in the same way.
Although periplasmic expression in E. coli is known to yield functional sc-Fv fragments (20) , consisting of two immunoglobulin V domains, addition of a third or fourth V domain by using peptide linkers completely abolished binding activity of periplasmic preparations, despite the presence of recombinant protein in sufficient amounts (data not shown). This shows that the periplasm ofE. coli is insufficient for functional expression of these antibody derivatives containing more than two immunoglobulin domains on a single polypeptide chain.
Cytotoxic Activity Against 17-lA-Positive Tumor Cells. The anti-17-lA-anti-CD3 bsc-Ab proved to be highly cytotoxic for several tumor cell lines in a 51Cr release assay (Fig. 5) . To approximate the in vivo conditions, we used unstimulated PBMCs from healthy donors as effector cells (26) . Lysis was found to be specific for the target antigen, as 17-lA-negative murine X63 plasmacytoma cells become susceptible to lysis after transfection with 17-lA cDNA. Different cell lines were not equally susceptible to bsc-Ab-mediated lysis, which may be explained by differences in the surface density of the target molecule (i.e., 17-lA-transfected X63 cells), the formation of target cell aggregates (i.e., , the expression of accessory A Immunology: Mack et aL Proc. Natl. Acad. Sci. USA 92 (1995) molecules (27) , or the susceptibility for the cytotoxic mechanisms of T lymphocytes (28) .
The kinetics of bsc-mediated cytotoxicity against Kato cells is shown in Fig. 6 . According to ref. 26 , we assume that only a subpopulation of the peripheral blood lymphocytes can be activated via CD3, so that one effector cell has to lyse several tumor cells with the need of additional time for reattachment and lysis. Further time may be necessary to bring unstimulated T cells into an activated state.
So far, all experiments have been performed with the short linker version of the bsc-Ab. To investigate the influence of the linker length between effector and target specificity on tumor cell lysis, we performed a 51Cr release assay using the longlinker version with an inter-Fv linker consisting of three instead of one Gly4-Ser, units. A longer linker should increase the flexibility of the molecule with a possible influence on specific lysis; however, no difference in tumor cell lysis was detectable in our assays (data not shown). the difficulties of conventional techniques of bispecific antibody production. As bsc-Ab molecules are correctly folded during the process of expression and secretion by mammalian cells, the described way of producing bsc-Abs yields a welldefined and homogeneous recombinant protein, which can easily be purified from culture supernatant by using a Cterminal histidine tail.
When compared with bsc-Ab production in E. coli (11, 12) , the various advantages of the presented eukaryotic expression are conspicuous: (i) renaturation of the protein is not necessary, (ii) antigen-specific affinity purification required to separate fully active bsc-Ab from inactive or partially active molecules can be avoided (many relevant antigens are not available in sufficient amounts for affinity purification!), and (iii) because of the DHFR amplification system, the yield of fully active bsc-Ab (15 mg/liter) exceeds that of bacterial expression.
The one-step procedure described here for generating functional bsc-Abs in CHO cells proved to be generally applicable, as it has been successfully done with other specificities (data not shown). Multispecific antibodies directed to three or more different antigens may now also be produced by the singlechain approach, so that the advantages of eukaryotic expression will become even more evident.
In other experiments, bsc-Ab-mediated cytotoxic activity was apparently not influenced by the length of the linker joining the two VH-VL pairs. Therefore, special measures to prevent wrong domain association do not seem to be absolutely necessary. However, in the interest of long-term stability, a short linker between the two different Fv fragments or a linker (34) .
Experiments with mouse models, using either nude athymic mice with transplanted human tumors (35) (36) (37) or immunocompetent mice with syngeneic tumors (7, 8, 38) , have demonstrated that T-cell retargeting leads to a significant survival benefit and tumor size reduction. Two clinical trials (39, 40) with autologous lymphocytes precoated with bispecific antibodies have also shown promising results. Therefore, we expect the new anti-17-lA-CD3 bispecific antibody to be an ideal candidate for systemic administration in colorectal cancer patients with disseminated residual tumor cells after complete resection of their primary tumor. In this group of patients, even an intact murine monoclonal antibody led to a significantly increased 5-year survival. Efficient expression of functional bispecific single-chain antibodies in eukaryotic cells should make the bispecific technology more amenable for other applications, which so far have been hampered by the limited availability of these interesting molecules.
